Over 2800 clinical strains of the Bacteroides fragilis group were collected during a 5-year period from ten geographically separate sites and tested for their susceptibility to various antimicrobial agents using a broth microdilution method. Among the cephalosporins, ceftizoxime was the most active (13% resistance) and importantly exhibited relatively equal activity against both B. fragilis species and non-B, fragilis species. Cefotaxime exhibited similar activity with an overall resistance rate of 18%. Both ceftriaxone and cefoperazone were appreciably less active cephalosporins especially against non-B, fragilis species. With regard to cephamycins, cefoxitin (MIC9o, 32 ~g/ml) was more active than cefotetan (MIC9o, >1256 ~,g/ml) and cefmetazole (MIC9o , 64 p, g/ml) . Non-B. fragilis species were highly resistant to cefotetan and cefmetazole. Imipenem was highly active against all strains with the exception of four strains of B. fragilis. Ampicillin-sulbactam, amoxicillin-clavulanate, piperacillin-tazobactam, and cefoperazone-sulbactam were all highly active with resistance rates <2%. No resistance was detected to metronidazole, whereas 14% of isolates were resistant to clindamycin. When compared with other studies, these findings underscore the wide variability in susceptibility patterns reported nationwide and the need to continue monitoring these patterns to aid in choosing the most active compounds for therapy.
INTRODUCTION
The importance of anaerobic bacteria in mixed aerobic-anaerobic infections is well established (Finegold and George, 1989) . Members of the Bacteroides fragilis group are the most important and most frequently isolated anaerobes from human infections.
Of the various species within the B. fragilis group, the B. fragilis species is the most commonly isolated and tends to be the most susceptible to a variety of antimicrobial agents, especially ~-lactams (Aldridge et al., 1984; Tally et al., 1985) . It must be emphasized, however, that members of the non-B, fragilis species (B. distasonis, B. ovatus, B. thetaiotaomicron, and B. vulgatus) can comprise from 35% to 45% of the clinical isolates of the B. fragilis group (Brook, 1988; Cuchural et al., 1988) . Furthermore, strains of the non-B, fragilis species tend to be highly resistant to certain antibiotics, especially [~-lactams Aldridge and Sanders, 1987; Goldstein and Citron, 1988) . We performed a 5-year, multicenter study of the in vitro susceptibility of clinical isolates of the B. fragilis group. This report details the results of that study from 1987 to 1991. Some of our results contrast with those of other recent multicenter studies.
MATERIALS AND METHODS

Organisms
Over a 5-year period, clinical isolates of the B. fragilis group were collected from ten medical centers within the United States and sent to a single reference laboratory (Louisiana State University in New Orleans) for susceptibility testing. A total of 2876 strains were tested, comprised of 1681 B. fragilis, 484 B. thetaiotaomicron, 329 B. ovatus, 181 B. distasonis, 165 B. vulgatus, 25 B. uniformis, 10 B. caccae, and 1 B. eggerthi. All isolates were identified by using selective media, biochemical profiles, and gas-liquid chromatography (Jousimies-Somer and Finegold, 1991; Holdeman et al., 1977; Summanen et al., 1993) . The sources of these isolates included abscesses, tissue, blood, body fluids, wounds, gastrointestinal and respiratory specimens, and bone. Because of changes in the antimicrobial composition in the test panels during the 5 years, not all strains were tested against each antimicrobial agent. 
Antimicrobial Agents
Antimicrobial Susceptibility Testing
Each strain was tested by a broth microdilution method as recommended by the National Committee for Clinical Laboratory Standards (NCCLS, 1988) . Serial twofold dilutions of each antimicrobial agent (or combination) were prepared using anaerobe broth MIC (Difco) within a dilution scheme of 0.01 to 256 tzg/ml. When combining ampicillin or cefoperazone with sulbactam, or amoxicillin with clavulanate, a 2:1 ratio was used. Piperacillin was combined with tazobactam in an 8:1 ratio or a constant tazobactam concentration of 4 b~g/ml. The inoculum of each strain was prepared by inoculating 3-5 colonies into 5 ml of pre-reduced anaerobe broth MIC and incubating for 3-6 h anaerobically at 35°C. The broth culture was then adjusted to a density equal to a no. 1 McFarland nephelometer standard and further diluted to give a final inoculum size of 1 x 105 colony forming units per well (1 x 10 6 CFU/ ml). All plates were incubated for 48 h at 35°C anaerobically and then read. The MIC (minimum inhibitory concentration) was defined as the lowest concentration of each antimicrobial agent (or combination) that inhibited the visible growth of the test isolate. If trailing end points were observed, the antimicrobial concentration where the most significant reduction of growth was observed was chosen as the MIC. With each susceptibility run, quality assurance was performed with B. fragilis American Type Culture Collection (ATCC) 25285, B. thetaiotaomicron ATCC 29741, and Eubacterium lentum ATCC 43055.
~-Lactamase Assay
Production of ~-lactamase was detected by using a nitrocephin test (Cefinase; BBL, Cockeysville, MD, USA). Table 1 compares the in vitro activity of the various antimicrobial agents against the B. fragilis group.
RESULTS
Ceftizoxime was the most active cephalosporin with (1992) or manufacturer recommendations, the following MICs (~,g/ml) were used as the resistant cutoff values: ~8, clindamycin and amoxicillin-clavulanate; ~>16, imipenem; >~32, metronidazole and ampicillin-sulbactam; ~>64, ceftizoxirae, cefotaxime, cefoperazone, ceftriaxone, cefoxitin, cefotetan, cefmetazole, and cefoperazone-sulbactam; and 1>128, mezlocillin, piperacillin, and piperacillin-tazobactam. only 13% of the isolates being resistant and was followed by cefotaxime, cefoperazone, and ceftriaxone with resistance rates of 18%, 34%, and 34%, respectively. Among the cephamycins, resistance to cefoxitin was 6% compared with 27% and 20% to cefotetan and cefmetazole, respectively. Imipenem was the most active [3-1actam agent tested, with an MICgo of 0.25 ~g/ml and a resistance rate of 0.1%. Both piperacillin and mezlocillin showed comparable activity, with a 12% resistance rate for each. The addition of a [3-1actamase inhibitor to selected [3-1ac-tams appreciably enhanced the activity of the latter compounds. A comparison of MICg0 of the ~-lactam-~-lactamase inhibitor combinations indicated that amoxicillin-clavulanate was only slightly more active than ampicillin-sulbactam but eightfold more active than cefoperazone-sulbactam and piperacillin-tazobactam. Resistance rates to the combinations were low, with piperacillintazobactam having the lowest resistant rate (0.2%).
Resistance to clindamycin among the B. fragilis group was 14%, whereas no metronidazole resistance was detected. fragilis group by test year. In general, increases in resistance over the 5 years were noted for the cephalosporins and cephamycins. Among the cephalosporins, cefoperazone resistance increased the most from 28% in 1987 to 41% in 1991. Both ceftizoxime and cefotaxime had a 5% variation in resistance rates during the testing years while ceftriaxone resistance remained in the low to middle 30 percentages during the same period. Among cephamycins, cefotetan showed a variation in resistance rates from 22% to 31%. Cefmetazole was tested only during 1989 and the resistance rate was 20% among those isolates. Cefoxitin resistance remained <10% for each test year. Resistance rates to piperacillin and mezlocillin were similar for all years tested, but overall piperacillin resistance increased slightly more among the isolates than did resistance to mezlocillin. For imipenem and the [3-1actam-~-lactamase inhibitor combinations, no consistent increase in resistance rates were observed. However, the resistance rates to clindamycin increased almost fourfold (5%-18%) during the 5-year period. (Nord et al., 1985) . Although the most common [3-1actamases from these isolates are characterized as cephalosporinases, some B. fragilis group strains elaborate ~-lactamases capable of destroying antimicrobials considered [3-1actamase stable such as cefoxitin, imipenem, and piperacillin (Cuchural et al., 1983; Sato et al., 1982) . Moreover, ~-lactamasemediated cefoxitin resistance among strains of the B. fragilis group has been shown to be transferable (Cuchural et al., 1986a) .
Results of the present study confirm that there are significant differences in the activity of certain antimicrobial agents against B. fragilis group isolates. Among the single agents tested, metronidazole and imipenem were the most active. Among the cephalosporin compounds, ceftizoxime was more active than cefotaxime, cefoperazone, and ceftriaxone, while among cephamycins, cefoxitin was more active than cefotetan and cefmetazole. Piperacillin, mezlocillin, and clindamycin had comparable resistance rates. With the exception of imipenem, the non-B, fragilis species were significantly more resistant to the [3-1actam antimicrobials alone (no [3-1actamase inhibitor) than were strains of the B. fragilis species; a similar pattern was seen with clindamycin.
Prevention of ~-lactam degradation by addition of a [3-1actamase inhibitor has proven to be very effective. The addition of sulbactam, clavulanate, or tazobactam significantly reduced the resistance rates to the accompanying ~-lactams and potentiated the activity of the antimicrobials by reducing the mode MICs and MICgo up to 32-fold and 64-fold, respectively. One strain of B. fragilis resistant to all of the [3-1actam-[3-1actamase inhibitor combinations except piperacillin-tazobactam was also resistant to all other [3-1actams tested. This strain probably produces the metallo-containing [3-1actamase enzyme that has been shown to destroy all penicillins and cephalosporins (Cuchural et al., 1986b) .
A comparison of our data with the recent US reports by Cuchural et al. (1988 and shows similarities and differences. Overall, the two reports correlated well with regard to resistance rates to imipenem, cefoxitin, piperacillin, cefoperazone, and clindamycin. However, reported resistance rates of 22%, 23%, and 14% to ceftizoxime, cefotaxime, and cefotetan, respectively, differed from our results showing resistance rates of 13%, 18%, and 27% to the same antimicrobials. Furthermore, the ceftizoxime MIC90 in our study was 64 ~g/ml compared with I>128 p,g/ml in their study. Our ceftizoxime data are in contrast to theirs and, from a comparison of our in vitro data, we can conclude that ceftizoxime has good coverage against B. fragilis group isolates with Bennion et al. (1992) in patients with perforated or gangrenous appendicitis with peritonitis reported that ceftizoxime exhibited good antianaerobic coverage. These differences in in vitro results are probably related to differences in susceptibility testing methodologies (Aldridge and Sanders, 1987; Aldridge et al., 1990) . Other US investigators have reported the high level of activity with ~-lactam-f~-lactamase inhibitor combinations with results similar to ours. Barry et al. (1986) reported that sulbactam reduced the MIC90 of ampicillin and cefoperazone from i>16 ~,g/ml to 2 ~g/ml and from 128 ~g/ml to 16 ~g/ml, respectively. Wexler et al. (1985) showed an MICgo reduction from ~256 ~g/ml to 8 ~g/ml when sulbactam was added to ampicillin. Clavulanate has been reported to increase the activity of amoxicillin 16-fold (Barry et al., 1986) . Appelbaum et al. (1986) have also shown a significant increase in the activity of piperacillin in the presence of tazobactam (YTR 830). In our study, ampicillin-sulbactam and amoxicillinclavulanate appeared to be slightly more active (MICs) than the other ~-lactam-~-lactamase inhibitor combinations; however, no appreciable differences in resistance rates were noted. Currently the approach of protecting ~-lactams with ~-lactamase inhibitors appears to remain highly effective. Phillips et al. (1992) reported on an in vitro survey of the susceptibility of B. fragilis group by using broth microdilution testing of isolates from 15 European and Scandinavian countries. Their results were similar to ours with regard to amoxicillinclavulanate, cefoxitin, cefotetan, imipenem, and metronidazole. Similarly we found imipenem resistance among B. fragilis strains. Notable differences for overall results were that mezlocillin resistance was 12% in our study versus 6% in theirs, and clindamycin resistance was higher in our study (14% versus 9%). Our higher rates of clindamycin resistance more closely agree with reports from Spain and France (Dubreuil et al., 1992; Reig et al., 1984; Garcia-Rodriquez and Garcia-Sanchez, 1985) . In Japan, a report by Watanabe et al. (1992) described susceptibility patterns of B. fragilis and B. thetaiotaomicron strains. Resistance to imipenem was found among both groups of isolates, with resistance rates of 1.6% and 3.4%, respectively. They also reported good activity for ceftizoxime and cefoperazonesulbactam similar to ours. For the two test groups, they reported clindamycin resistances of 24% and 27.5%, respectively. Moreover, their piperacillin re-sistance rate among B. thetaiotaomicron was 26.8% compared with our 13%. Fortunately no metrondazole resistance was noted.
This study has shown that a variety of susceptibility patterns can be observed among strains of the B. fragilis group. Currently metronidazole, imipenem, and the ~-lactam-~-lactamase inhibitor combinations are the most active. Good activity was also seen for mezlocillin, piperacillin, ceftizoxime, cefoxitin, and clindamycin. Because of reports of resistance to metronidazole, imipenem, and other antimicrobials among anaerobes (Breuil et al., 1989; Brogan et al., 1989; LaMothe et al., 1986) , additional in vitro studies to monitor changes in susceptibility patterns are warranted not only in the United States but elsewhere.
